Cited by 332Schizophrenia research and treatmentTreatment of Major DepressionMental Health and Psychiatry

The DOI matches its Crossref record; 116 of the 118 references it cites were found in a registry or an index.

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Open access

Remington, Gary, Addington, Donald, Honer, William, Ismail, Zahinoor, Raedler, Thomas, Teehan, Michael·2017·The Canadian Journal of Psychiatry

DOI 10.1177/0706743717720448PMC PMC5593252

Open this paper in CoChat — free account Open PDF

Abstract

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Results: Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. Conclusions: In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.

Integrity signals

Registry

Crossref · 10.1177/0706743717720448

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
The Scottish Intercollegiate Guidelines Network (SIGN)
Miller, J. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020010401 · Cited by 1,546
Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citation
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis.
Penttilä, M., Jääskeläinen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127753 · Cited by 716

Show all 118 references

Research works printed but not linked: 12

National Collaborating Centre for Mental Health, 2013, National Clinical Guideline Number, 155
Agid O, 2006, J Psychiatry Neurosci, 31, 93
Kane JM, 1996, J Clin Psychiatry, 57, 35
Asenjo Lobos C, 2010, Cochrane Database Syst Rev, CD006633
Rhoades HM, 1988, Psychopharmacol Bull, 24, 101
Woerner MG, 1988, Psychopharmacol Bull, 24, 112
Powney MJ, 2012, Cochrane Database Syst Rev, 11, CD009377
Gillies D, 2013, Cochrane Database Syst Rev, 4, CD003079
Volavka J, 2013, Psychiatr Danub, 25, 24
Kane JM, 2003, J Clin Psychiatry, 64, 5
Whitehead C, 2002, Cochrane Database Syst Rev, CD002305
Cipriani A, 2011, BMJ Clin Evid, 1

Sorted by citations

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 168
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
Correll, C. U., Newcomer, J. W., Silverman, B. L., DiPetrillo, L., Graham, C. E., Jiang, Y., Du, Y., Simmons, A., Hopkinson, C., McDonnell, D., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19121279 · Cited by 123
Brain stimulation and other biological non-pharmacological interventions in mental disorders: An umbrella review
Rosson, S., de Filippis, R., Croatto, G., Collantoni, E., Pallottino, S., Guinart, D., Brunoni, A. R., Dell’Osso, B. M., Pigato, G., Hyde, J., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104743 · Cited by 120
The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review
Fiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110
Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate
Dempster, K., Jeon, P., Mackinley, M., Williamson, P., Théberge, J., & Palaniyappan, L. K. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0704-x · Cited by 94
Emerging evidence for astrocyte dysfunction in schizophrenia
Figueiredo, E. C. D. O., Calì, C., Petrelli, F., & Bezzi, P. (2022) · Glia · doi:10.1002/glia.24221 · Cited by 87
Alterations of Astrocytes in the Context of Schizophrenic Dementia
Tarasov, V. V., Svistunov, A. А., Chubarev, V. N., Sologova, S. S., Мухортова, П. А., Levushkin, D., Somasundaram, S. G., Kirkland, C. E., Бачурин, С. О., & Aliev, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01612 · Cited by 85
A Focused Review of the Metabolic Side-Effects of Clozapine
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609240 · Cited by 98
Self-citation
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis
Ostuzzi, G., Bertolini, F., Giovane, C. D., Tedeschi, F., Bovo, C., Gastaldon, C., Nosè, M., Ogheri, F., Papola, D., Purgato, M., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20071120 · Cited by 86
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
Clozapine haematological monitoring for neutropenia: a global perspective
Oloyede, E., Blackman, G., Whiskey, E., Bachmann, C., Dzahini, O., Shergill, S. S., Taylor, D. M., McGuire, P. K., & MacCabe, J. H. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602200066x · Cited by 77
Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects
Orsolini, L., Pompili, S., & Volpe, U. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175040 · Cited by 89
Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis
Polese, D., Fornaro, M., Palermo, M., Luca, V. D., & de Bartolomeis, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00210 · Cited by 78
Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort
Fond, G. B., Godin, O., Boyer, L., Berna, F. S., Andrianarisoa, M., Coulon, N., Brunel, L., Bulzacka, E., Aouizerate, B., Capdevielle, D., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0908-0 · Cited by 70
Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.013 · Cited by 67
Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth
Abidi, S., Mian, I. A., Ortega, I., Lecomte, T., Raedler, T. J., Jackson, K., Jackson, K., Pringsheim, T. M., & Addington, D. E. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720197 · Cited by 66
Self-citation
Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern
John, A. P., Ko, E. K. F., & Dominic, A. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718772522 · Cited by 60
Brexpiprazole: A Review in Schizophrenia
Frampton, J. E. (2019) · Drugs · doi:10.1007/s40265-019-1052-5 · Cited by 57
Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysis
Campana, M., Falkai, P., Siskind, D. J., Hasan, A., & Wagner, E. M. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.002 · Cited by 56
Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study
Takaesu, Y., Watanabe, K., Numata, S., Iwata, M., Kudo, N., Oishi, S., Takizawa, T., Nemoto, K., Yasuda, Y., Tagata, H., et al. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12911 · Cited by 51
Efficacy of long‐acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta‐analysis
Lian, L., Kim, D. D., Procyshyn, R. M., Fredrikson, D. H., Cázares, D., Honer, W. G., & Barr, A. M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13202 · Cited by 47
Self-citation
Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies
Liu, Y., Xu, J. L., Fang, K., Xu, Y., Gao, J., Zhou, C., Tang, X., Fang, X., Chen, J., Xie, C., et al. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320982720 · Cited by 47
A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder
Faden, J., & Citrome, L. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.008 · Cited by 45
State of the Science: The Hierarchical Taxonomy of Psychopathology (HiTOP)
Cicero, D. C., Ruggero, C. J., Balling, C. E., Bottera, A. R., Cheli, S., Elkrief, L., Forbush, K. T., Hopwood, C. J., Jonas, K. G., Jutras‐Aswad, D., et al. (2024) · Behavior Therapy · doi:10.1016/j.beth.2024.05.001 · Cited by 57
Switching to Antipsychotic Monotherapy vs. Staying on Antipsychotic Polypharmacy in Schizophrenia: A Systematic Review and Meta-Analysis
Matsui, K., Tokumasu, T., Takekita, Y., Inada, K., Kanazawa, T., Kishimoto, T., Takasu, S., Tani, H., Tarutani, S., Hashimoto, N., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.030 · Cited by 41
Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase®
Chrétien, B., Lelong‐Boulouard, V., Chantepie, S., Sassier, M., Bertho, M., Brazo, P., Humbert, X., Alexandre, J., Fédrizzi, S., & Dolladille, C. (2020) · Psychological Medicine · doi:10.1017/s0033291720000161 · Cited by 39
Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view
Ferreira, V., Grajales, D., & Valverde, Á. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.158534 · Cited by 41
Sudden death in schizophrenia
Li, K. J., Greenstein, A. P., & DeLisi, L. E. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000403 · Cited by 37
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R., & Muscatello, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 43
A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia
Hui, C. L. M., Lam, B. S. T., Lee, E. H. M., Chan, S. K. W., Chang, W. C., Suen, Y. N., & Chen, E. Y. H. (2019) · International Review of Psychiatry · doi:10.1080/09540261.2019.1613965 · Cited by 40
Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.040 · Cited by 38
The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples
Gäebel, W., Stricker, J. H., & Riesbeck, M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.049 · Cited by 35
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33
Potentially fatal outcomes associated with clozapine
Li, K. J., Gurrera, R. J., & DeLisi, L. E. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.058 · Cited by 32
The Role of Board-Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes
Goldstone, L. W., DiPaula, B. A., Werremeyer, A. B., Botts, S. R., Hepburn, B. M., Liu, H. Y., Duckworth, K., Young, A. S., & Kelly, D. L. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000066 · Cited by 32
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study
Ochi, S., Tagata, H., Hasegawa, N., Yasui‐Furukori, N., Iga, J., Kashiwagi, H., Kodaka, F., Komatsu, H., Tsuboi, T., Tokutani, A., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac036 · Cited by 29
Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis
Olagunju, A. T., Clark, S. R., & Baune, B. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0565-x · Cited by 30
Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial
Zadeh, E. M., Bayanati, S., Ziafat, K., Rezaei, F., Mesgarpour, B., & Akhondzadeh, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120909416 · Cited by 29
Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: A systematic review
Ercis, M., Sánchez-Ruiz, J. A., Webb, L. M., Solares‐Bravo, M., Betcher, H. K., Moore, K. M., Frye, M. A., Veldić, M., & Özerdem, A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.038 · Cited by 28
Acute conceptual disorganization in untreated first-episode psychosis: a combined magnetic resonance spectroscopy and diffusion imaging study of the cingulum
Pan, Y., Dempster, K., Jeon, P., Théberge, J., Khan, A. R., & Palaniyappan, L. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200167 · Cited by 28
Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight
Ferreira, V., Folgueira, C., Guillén, M., Zubiaur, P., Navares, M., Sarsenbayeva, A., López-Larrubia, P., Eriksson, J. W., Pereira, M. J., Abad‐Santos, F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155335 · Cited by 29
A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries
Ismail, D., Tounsi, K., Zolezzi, M., & Eltorki, Y. H. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.12.011 · Cited by 27
Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia
Hatta, K., Hasegawa, H., Imai, A., Sudo, Y., Morikawa, F., Katayama, S., Watanabe, H., Ishizuka, T., Nakamura, M., Misawa, F., et al. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.02.005 · Cited by 26
Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment
Ghabrash, M. F., Coronado‐Montoya, S., Aoun, J., Gagné, A.-A., Mansour, F., Ouellet‐Plamondon, C., Trépanier, A., & Jutras‐Aswad, D. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112890 · Cited by 30
Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients
Ayani, N., Morimoto, T., Sakuma, M., Kikuchi, T., Watanabe, K., & Narumoto, J. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001416 · Cited by 26
Schizophrenia: Antipsychotics and drug development
Remington, G. J., Hahn, M., Agarwal, S. M., Chintoh, A. F., & Agid, O. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113507 · Cited by 30
Self-citation
Conceptual disorganization and redistribution of resting-state cortical hubs in untreated first-episode psychosis: A 7T study
Dey, A., Dempster, K., Mackinley, M., Jeon, P., Das, T. K., KHAN, A. R., Gati, J. S., & Palaniyappan, L. K. (2021) · Schizophrenia · doi:10.1038/s41537-020-00130-3 · Cited by 25
Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
Brown, B., Turkoz, I., Mancevski, B., & Mathews, M. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12868 · Cited by 23
Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant
Lin, C., Chen, Y.-M., & Lane, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191011163539 · Cited by 24
Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
Kim, D. D., Barr, A. M., Lian, L., Yuen, J. W. Y., Fredrikson, D. H., Honer, W. G., Thornton, A. E., & Procyshyn, R. M. (2021) · Schizophrenia · doi:10.1038/s41537-021-00158-z · Cited by 23
Self-citation
Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia
Suetani, S., Dark, F. L., Every‐Palmer, S., Galletly, C. A., O'Donoghue, B. N., Halstead, S., Keating, D., Korman, N., Lappin, J., Lawn, S., et al. (2026) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251406058 · Cited by 25
The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia
Nasyrova, R., Khasanova, A. K., Altynbekov, K. S., Asadullin, A., Markina, E. A., Gayduk, A., Shipulin, G., Petrova, M. M., & Shnayder, N. (2022) · Nutrients · doi:10.3390/nu14235142 · Cited by 16
Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study
Hasegawa, N., Yasuda, Y., Yasui‐Furukori, N., Yamada, H., Hori, H., Ichihashi, K., Takaesu, Y., Iida, H., Muraoka, H., Kodaka, F., et al. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13578 · Cited by 22
Easing the disruption of COVID-19: supporting the mental health of the people of Canada—October 2020—an RSC Policy Briefing
Asmundson, G. J. G., Blackstock, C., Bourque, M. C., Brimacombe, G., Crawford, A. S., Deacon, S. H., McMullen, K., McGrath, P. J., Mushquash, C. J., Stewart, S. H., et al. (2020) · FACETS · doi:10.1139/facets-2020-0082 · Cited by 23
Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives
Calzavara‐Pinton, I., Nibbio, G., Barlati, S., Bertoni, L., Necchini, N., Zardini, D., Baglioni, A., Paolini, S., Poddighe, L., Bulgari, V., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14080791 · Cited by 23
A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project
Yamada, H., Motoyama, M., Hasegawa, N., Miura, K., Matsumoto, J., Ohi, K., Yasui‐Furukori, N., Numata, S., Takeshima, M., Sugiyama, N., et al. (2022) · BJPsych Open · doi:10.1192/bjo.2022.44 · Cited by 21
Association between the examination rate of treatment‐resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study
Yasui‐Furukori, N., Muraoka, H., Hasegawa, N., Ochi, S., Numata, S., Hori, H., Hishimoto, A., Onitsuka, T., Ohi, K., Hashimoto, N., et al. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12218 · Cited by 21
Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach
Brodeur, S., Vanasse, A., Courteau, J., Courteau, M., Stip, É., Fleury, M., LESAGE, A. D., Demers, M., & Roy, M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13411 · Cited by 23
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review
Smessaert, S., Detraux, J., Desplenter, S., & Binder, M. D. (2024) · CNS Drugs · doi:10.1007/s40263-023-01054-z · Cited by 20
The Role of Astrocytes in the Molecular Pathophysiology of Schizophrenia: Between Neurodevelopment and Neurodegeneration
Vellucci, L., Mazza, B., Barone, A., Nasti, A., Simone, G. D., Iasevoli, F., & de Bartolomeis, A. (2025) · Biomolecules · doi:10.3390/biom15050615 · Cited by 23
Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
Puranen, A., Koponen, M., Lähteenvuo, M., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2023) · Schizophrenia · doi:10.1038/s41537-023-00364-x · Cited by 19
Dandy-Walker Malformation-Like Condition Revealed by Refractory Schizophrenia: A Case Report and Literature Review
Tréhout, M., Zhang, N., Blouet, M., Borha, A., & Dollfus, S. (2018) · Neuropsychobiology · doi:10.1159/000494695 · Cited by 18
Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
Pae, C. (2020) · Chonnam Medical Journal · doi:10.4068/cmj.2020.56.3.157 · Cited by 18
Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
Pae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.434 · Cited by 18
Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study
Zolk, O., Greiner, T., Schneider, M., Heinze, M., Dahling, V., Ramin, T., Grohmann, R., Bleich, S., Zindler, T., Toto, S., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.2011403 · Cited by 17
Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: similarities and differences
Kang, D., Lu, J., Liu, W., Shao, P., & Wu, R. (2022) · Schizophrenia · doi:10.1038/s41537-022-00211-5 · Cited by 17
Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study
Agid, O., Remington, G. J., Fung, C., Nightingale, N., Duclos, M., & Anger, G. J. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211055413 · Cited by 17
Self-citation
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
Lippi, M., Fanelli, G., Fabbri, C., Ronchi, D. D., & Serretti, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000417 · Cited by 20
Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
(2018) · Europe PMC (PubMed Central) · Cited by 17
Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States
Li, P., Benson, C. J., Geng, Z., Seo, S., Patel, C. A., & Doshi, J. A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2189859 · Cited by 16
Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond
Kane, J. M., Schoretsanitis, G., Rubio, J. M., & Correll, C. U. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.035 · Cited by 16
Glutamate modulators for treatment of schizophrenia
Zhand, N., Attwood, D. G., & Harvey, P. D. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.02.001 · Cited by 16
Clozapine-induced Myocarditis: Pathophysiologic Mechanisms and Implications for Therapeutic Approaches
Rabkin, S. W., & Tang, J. K. K. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220211094910 · Cited by 15
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
Kamei, H. (2022) · Medicina · doi:10.3390/medicina58111584 · Cited by 15
Dopamine partial agonists: a discrete class of antipsychotics
Taylor, D. M., Chithiramohan, R. N., Grewal, J., Gupta, A., Hansen, L. K., Reynolds, G. P., & Pappa, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2151473 · Cited by 15
A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse
Tsimpili, H., & Zoidis, G. (2025) · Pharmaceuticals · doi:10.3390/ph18030369 · Cited by 15
The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder
Alphs, L. D., Brown, B., Turkoz, I., Baker, P. C., Fu, D., & Nuechterlein, K. H. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.02.019 · Cited by 16
Clozapine-Related Myocarditis and Rechallenge
Noël, M.-C., Powell, V., Burton, L., Panda, R., & Remington, G. J. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001062 · Cited by 15
Self-citation
Barriers and facilitators of exploiting the potential of value-added medicines
Petykó, Z. I., Inotai, A., Holtorf, A., Brixner, D. I., & Kaló, Z. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1758558 · Cited by 15
Pipette-tip micro-solid phase extraction based on melamine-foam@polydopamine followed by ultra-high-performance liquid chromatography–quadrupole–time-of-flight mass spectrometry for detection of psychotropic drugs in human serum
He, X., Sun, T., Wang, L., & Jiang, X. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122499 · Cited by 15
How can we best help this patient? Exploring mental health therapists’ reflections on medication-free care for patients with psychosis in Norway
Oedegaard, C., Ruano, A. L., Blindheim, A., Veseth, M., Stige, B., Davidson, L., & Engebretsen, I. (2022) · International Journal of Mental Health Systems · doi:10.1186/s13033-022-00529-8 · Cited by 7
Psychiatric and non-psychiatric polypharmacy among older adults with schizophrenia: Trends from a population-based study between 2000 and 2016
Lunghi, C., Rochette, L., Massamba, V. K., Tardif, I., Ouali, A., & Sirois, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1080073 · Cited by 15
An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia
Neufeld, N. H., & Blumberger, D. M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250068 · Cited by 14
Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management
Kelly, D. L., & Love, R. C. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.03.064 · Cited by 16
Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
Woo, Y. S., Yoon, B.-H., Jeon, B.-H., Seo, J. S., Nam, B., Lee, S.-Y., Jae, Y. M., Jang, S., Eun, H. J., Won, S., et al. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.3.423 · Cited by 14
Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity
Kimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 16
Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies
Wu, B., Wu, L., He, Y., Yin, Z., & Deng, L. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2021.1934859 · Cited by 14
Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
Lynum, K. S. B., Turkoz, I., & Kim, E. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12685 · Cited by 14
Clinically Relevant Anti-Neuronal Cell Surface Antibodies in Schizophrenia Spectrum Disorders
Colijn, M. A., & Ismail, Z. (2019) · Neuropsychobiology · doi:10.1159/000499714 · Cited by 14
Self-citation
Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program
Borrelli, E. P., Lee, E. Y., & Caffrey, A. R. (2020) · Mental Health Clinician · doi:10.9740/mhc.2020.05.070 · Cited by 14
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13
“51 Unfortunately, one limitation of using clinical markers to inform subsequent treatment decisions is that they rely on trial and error, which means longer time experiencing symptoms until the optimal treatment is identified.”
Background
Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years
Yasui‐Furukori, N., Kawamata, Y., Sasaki, T., Yokoyama, S., Okayasu, H., Shinozaki, M., Takeuchi, Y., Sato, A., Takaaki, I., Komahashi‐Sasaki, H., et al. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s390482 · Cited by 13
Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options
Rubio, J. M., Guinart, D., Kane, J. M., & Correll, C. U. (2023) · CNS Drugs · doi:10.1007/s40263-023-01009-4 · Cited by 13
Patterns of prescription of antipsychotics in Qatar
Ouanes, S., Becetti, I., Ghuloum, S., Hammoudeh, S., Shehata, M., Ghabrash, H., Yehya, A., Lawati, H. J. A., AlFakhri, N., Iram, H., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241986 · Cited by 12
Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study
García‐Portilla, M. P., Ruiz, A. B., Robina, F. G., Dorado, M. G., & Rengel, P. M. L. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2023496 · Cited by 12
Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition
Ferreira, V., Folgueira, C., García‐Altares, M., Guillén, M., Ruíz-Rosario, M., Nunzio, G. D., García‐Martinez, I., Alén, R., Bookmeyer, C., Jones, J. G., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102741 · Cited by 12
Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients With Schizophrenia. Implications for Clinical Practice
Monteleone, P., Amore, M., Cabassi, A., Clerici, M., Fagiolini, A. M., Girardi, P., Jannini, E. A., Maina, G., Rossi, A., Vita, A., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00842 · Cited by 12
Schizophrenia Psychosis in Women
Seeman, M. V. (2020) · Women · doi:10.3390/women1010001 · Cited by 13
The Role of Tele-Education in Advancing Mental Health Quality of Care: A Content Analysis of Project ECHO Recommendations
Sockalingam, S., Kirvan, A., Pereira, C., Rajaratnam, T., Elzein, Y., Serhal, E., & Crawford, A. (2021) · Telemedicine journal and e-health · doi:10.1089/tmj.2021.0122 · Cited by 12

Authors: Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M.
Affiliations: Centre for Addiction and Mental Health (CA)
University of Calgary (CA)
University of British Columbia (CA)
Dalhousie University (CA)
Corresponding author: Remington, Gary
ORCID: Remington, Gary
Addington, Donald
Honer, William
Ismail, Zahinoor
Raedler, Thomas
Venue: The Canadian Journal of Psychiatry
Publisher: SAGE Publications
Published: 2017-07-13
Volume: 62
Issue: 9
Pages: 604-616
ISSN: 0706-7437 (ISSN-L)
1497-0015
DOI: 10.1177/0706743717720448
PMC: PMC5593252
OpenAlex: W2737472140
Cited by: 332
References: 118
Citations by year: 2026: 29 · 2025: 32 · 2024: 46 · 2023: 38 · 2022: 66 · 2021: 56 · 2020: 23 · 2019: 28 · 2018: 13 · 2017: 1
FWCI: 14.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: The Canadian Journal of Psychiatry (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Hotchkiss Brain Institute, University of Calgary
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: schizophrenia, pharmacotherapy, adults, first-episode schizophrenia, acute exacerbation, relapse prevention, maintenance therapy, treatment-resistant schizophrenia, clozapine-resistant schizophrenia, antipsychotic drugs, symptom domains, evidence-based recommendations
MeSH terms: Adult, Canada, Humans, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks